BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT04514497

Title field or adapter rule

{'original_value': 'BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:26.167555+00:00

Published At

2026-05-19T00:00:00+00:00

Record Updated At

2026-09-10

Results Posted At

2026-05-19

Source Retrieved At

2026-10-31T22:17:56.788771+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Metastatic Lung Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Neuroendocrine Carcinoma", "Metastatic Pancreatic Adenocarcinoma", "Stage III Lung Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Lung Small Cell Carcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Neuroendocrine Carcinoma", "Unresectable Pancreatic Adenocarcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-09-10", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT04514497"

protocolSection.identificationModule.officialTitle

"BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

{"date": "2026-05-19", "type": "ACTUAL"}

Study condition terms

• Metastatic Lung Small Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
• Metastatic Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Stage III Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Stage III Pancreatic Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Stage IV Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Stage IV Pancreatic Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Unresectable Lung Small Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Unresectable Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
• Unresectable Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
• Unresectable Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Cohort I (elimusertib, irinotecan)', 'Cohort II (elimusertib, irinotecan)', 'Cohort III (elimusertib, topotecan)'], 'description': 'Undergo tumor biopsy', 'name': 'Biopsy Procedure', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort I (elimusertib, irinotecan)', 'Cohort II (elimusertib, irinotecan)', 'Cohort III (elimusertib, topotecan)'], 'description': 'Undergo collection of blood samples', 'name': 'Biospecimen Collection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort I (elimusertib, irinotecan)', 'Cohort II (elimusertib, irinotecan)', 'Cohort III (elimusertib, topotecan)'], 'description': 'Undergo CT', 'name': 'Computed Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort I (elimusertib, irinotecan)', 'Cohort II (elimusertib, irinotecan)', 'Cohort III (elimusertib, topotecan)'], 'description': 'Given PO', 'name': 'Elimusertib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort I (elimusertib, irinotecan)', 'Cohort II (elimusertib, irinotecan)'], 'description': 'Given IV', 'name': 'Irinotecan Hydrochloride', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort I (elimusertib, irinotecan)', 'Cohort II (elimusertib, irinotecan)', 'Cohort III (elimusertib, topotecan)'], 'description': 'Undergo MRI', 'name': 'Magnetic Resonance Imaging', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort III (elimusertib, topotecan)'], 'description': 'Given IV', 'name': 'Topotecan Hydrochloride', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Elimusertib (protocolSection.armsInterventionsModule.interventions[].name)
• Irinotecan Hydrochloride (protocolSection.armsInterventionsModule.interventions[].name)
• Topotecan Hydrochloride (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.